Thus, NK cells may be considered potential immunotherapy for DN-CML patients where blocking TIGIT on PB NK cells could reverse their immune suppression and targeting CD57 on BM NK cells could stimulate their proliferation in future treatment paradigms. The gene discussed is TIGIT; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.